GSK Posts Strong Q2 Growth, Specialty Medicines Drive Global Profit Rise

GSK reported strong second-quarter financial results in 2025, driven primarily by double-digit sales growth in its Specialty Medicines division, including significant gains in Respiratory, Immunology & Inflammation, Oncology, and HIV. The company beat revenue and profit expectations, with second-quarter sales reaching nearly £8 billion and core operating profit rising 12%, prompting GSK to raise its full-year guidance to the top end of its previous forecast ranges. CEO Emma Walmsley highlighted robust R&D progress, including three major FDA approvals so far in 2025 and 16 assets in late-stage development, with additional promising treatments expected to enter pivotal trials by year-end. Despite ongoing trade uncertainties and tariff threats from President Trump, GSK stated it is well-positioned to mitigate any financial impact, supported by the recent US-EU trade deal and internal mitigation strategies. Furthermore, GSK is engaged in discussions with the Trump administration about sustainable drug pricing in the U.S., aiming to ensure discounts are passed on to patients while maintaining industry viability. The company remains confident in its long-term outlook, supported by continued growth in specialty medicines and a strong pipeline.